KSC:001060
JW Pharmaceutical Corporation · KSC · Healthcare · KRW · FY for 2025
Figures on this page computed 2026-11-08 12:57 UTC
Last close
n/aKRW
Market data
8.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
- Computed from the filing for 2025
15.8%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
8.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
10.9%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.15Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
2.0%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
Growth is the furthest below its sector's middle: 0.43 against 0.50 on the market's range.
Follow one won
lens 1 of 9After what it costs to make
46.4%
After running the business
11.3%
After interest and tax
8.0%
After what it must reinvest
10.9%
Kept after the dividend
9.5%
The five stops
5 of 5 read- After what it costs to make359,313,884,00046.4%
- After running the business87,876,681,00011.3%
- After interest and tax61,688,754,0008.0%
- After what it must reinvest84,624,504,00010.9%
- Kept after the dividend73,556,295,0009.5%
Of every unit of sales, 0.09 is still there after the dividend.
Of every unit of sales, 0.09 is still there after the dividend.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales774,800,812,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
After what it costs to make359,313,884,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
After running the business87,876,681,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
After interest and tax61,688,754,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
After what it must reinvest84,624,504,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
Kept after the dividend73,556,295,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW